VEERUPAXAGOUDA PATIL

About

A resourceful scientist with over 13 years of broad expertise in immunology, cell biology, cancer immunotherapy, and host-pathogen interactions. Proven ability to support preclinical sciences for immunology, cancer immunotherapy and host-pathogen interactions.

Employment

• University of Louisville Lab Researcher
  2025 - Present
• Georgetown University School of Medicine Postdoctoral Fellow
  2023 - 2024
• University of Maryland, College Park Faculty Specialist
  2023 - 2023
• The Ohio State University Research Associate 1
  2019 - 2023
• University of Maryland Baltimore Postdoctoral Fellow
  2019 - 2019
• Georgetown University Lombardi Comprehensive Cancer Center Research Scientist
  2016 - 2019
• Karnataka Veterinary Animal and Fisheries Sciences University Assistant Professor (Adjunct Faculty)
  2014 - 2015
• Cordeliers Research Centre Postdoctoral Fellow
  2012 - 2013
• University of Medicine and Dentistry of New Jersey Postdoctoral Fellow
  2009 - 2012
• University of Vermont Postdoctoral Fellow
  2007 - 2009

Education

• Indian Institute of Science PhD
  1999 - 2007
• Karnataka Veterinary Animal and Fisheries Sciences University MVSc
  1997 - 1999
• Karnataka Veterinary Animal and Fisheries Sciences University BVSc & AH
  1992 - 1997

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Evaluation of Efficacy of Surface Coated versus Encapsulated Influenza Antigens in Mannose–Chitosan Nanoparticle-Based Intranasal Vaccine in Swine
  Vaccines 2024 DOI: 10.3390/vaccines12060647
  +Save
• Characterization of the Efficacy of a Split Swine Influenza A Virus Nasal Vaccine Formulated with a Nanoparticle/STING Agonist Combination Adjuvant in Conventional Pigs
  Vaccines 2023 DOI: 10.3390/vaccines11111707
  +Save
• Intradermal Vaccination against Influenza with a STING-Targeted Nanoparticle Combination Adjuvant Induces Superior Cross-Protective Humoral Immunity in Swine Compared with Intranasal and Intramuscular Immunization
  Vaccines 2023 DOI: 10.3390/vaccines11111699
  +Save
• Artificial Intelligence in Public Health: Revolutionizing Epidemiological Surveillance for Pandemic Preparedness and Equitable Vaccine Access
  Vaccines 2023 DOI: 10.3390/vaccines11071154
  +Save
• Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
  2023 DOI: 10.1158/2326-6066.c.6550626.v1
  +Save
• Data from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
  2023 DOI: 10.1158/2326-6066.c.6550626
  +Save
• Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
  2023 DOI: 10.1158/2326-6066.22544379.v1
  +Save
• Supplementary Figure from IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
  2023 DOI: 10.1158/2326-6066.22544379
  +Save
• IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status
  Cancer Immunology Research 2022 DOI: 10.1158/2326-6066.CIR-21-0457
  +Save
• Intravenous immunoglobulin suppresses the polarization of both classically and alternatively activated macrophages
  Human Vaccines & Immunotherapeutics 2020 DOI: 10.1080/21645515.2019.1602434
  +Save